DC Circ. Rejects Esai's Petition Over Seizure Med Delay

Law360, Chicago (October 25, 2013, 2:56 PM EDT) -- The D.C. Circuit on Tuesday shot down a bid from a U.S. unit of Japan’s Eisai Co. Ltd. to force the U.S. Drug Enforcement Administration to speed up the process for scheduling its epilepsy drug Fycompa as a controlled substance, saying the company had not shown the need for such drastic action.

In a brief order, the three-judge panel denied the drugmaker’s petition for a writ of mandamus. However, the decision came after the DEA agreed to take the initial step in the scheduling process by...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re: Eisai Inc.


Case Number

13-1243

Court

Appellate - DC Circuit

Nature of Suit

Date Filed

August 19, 2013

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.